All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your MDS Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.
As of January 1st, 2024, the MDS Hub will no longer be updated. Please continue to browse our archive for valuable content. For the latest updates in MDS, visit our sister site

Visual abstract | Enasidenib as monotherapy and in combination with azacitidine for patients with IDH2-mutated MDS: results from a phase II study

Oct 14, 2022
Learning objective: After reading this article, learners will be able to cite a new clinical development in myelodysplastic syndromes.

Bookmark this article

The MDS Hub is pleased to present a visual abstract representing key data from a phase II clinical trial (NCT03383575) evaluating enasidenib, both in combination with azacitidine and as monotherapy in patients with high-risk IDH2-mutated MDS. The safety and efficacy of enasidenib has been previously reported by the MDS Hub.

Visual Abstract

To download this visual abstract, click below.

Download here


Subscribe to get the best content related to MDS delivered to your inbox